Evidence map›Paper›PMID 35765007›Full record

ArticleDiagnostic pathology2022

Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China.

Chen Xu, Miaomiao Sun, Mei Jin, Zengshan Li, Rong Qin, Guoping Ren, Wenyong Sun, Lirong Chen, Lijuan Luan, Yalan Liu and 4 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02843412 (The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02843412 unknown statusnot on this map

The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry

TypeobservationalSponsorShanghai Zhongshan HospitalRan2016Enrolled2,000ConditionsGastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue BlocksArmschoose two tumor tissue paraffin blocks
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Miaomiao SunDepartment of Pathology, Henan Cancer Hospital, Zhenghou, Henan, China.
Mei JinDepartment of Pathology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Zengshan LiDepartment of Pathology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
Rong QinDepartment of Pathology, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, China.
Guoping RenDepartment of Pathology, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China.
Wenyong SunDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Lirong ChenDepartment of Pathology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China.
Lijuan LuanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yalan LiuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Dongxian JiangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lingli ChenDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. houyingyong@aliyun.com.
Sun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CNAir Force Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CNFirst Affiliated Hospital Zhejiang University · CNFudan University · CNHenan Cancer Hospital · CNZhejiang Cancer Hospital · CNZhejiang University · CN

Funding

Foundation for Excellent Young Doctors of Zhongshan Hospital 2019ZSYXGG19Shanghai Municipal Health Bureau shslczdzk 01302Shanghai Science and Technology Development Foundation 19MC1911000
6 · The paper itself

Abstract

backgroundFormer single center studies indicated that HER2 assessment with two primary tumor blocks (dual block HER2 assessment) could be an efficient and practical approach to overcome the adverse impact of heterogeneity and acquire a HER2 positive rate in gastric cancer (GC). This multicenter prospective clinical trial (NCT02843412) was launched to verify its value and generality.

methodsA total of 3806 participants with primary GCs have been enrolled from 8 hospitals in China. Two primary tumor blocks were selected and recorded as block 1 and block 2 after histological evaluation. An HER2 (4B5) rabbit monoclonal antibody was used for the immunohistochemistry (IHC) analysis.

resultsIn total patients, HER2 IHC positive (3+) rate with dual block assessment (9.4%) was higher than that with single block assessment (block 1: 7.8%, block 2: 7.8%) (P < 0.001). Compared with single-block assessment, dual-block assessment increased the positive rate by approximate 20%. Similarly, HER2 equivocal (2+) rate was increased in dual block assessment (25.8%), which was higher than that in single block assessment (block 1: 20.3%, block 2: 20.9%) (P < 0.001). Conversely, dual block assessment demonstrated a lower HER2 negative (0/1+) rate (64.8%) than single block assessment (block1: 71.9%, block 2: 71.3%) (P < 0.001). These findings were also confirmed in individual hospitals.

conclusionsDual block HER2 assessment effectively increased HER2 IHC positive rate in resected specimens of GC. We recommended dual block HER2 assessment be promoted in routine clinical practice in GC.

trial registrationClinicalTrials.gov, NCT02843412 . Registered 1 July 2016 - Retrospectively registered.

Indexed as

Stomach NeoplasmsBiomarkers, TumorChinaErb-b2 Receptor Tyrosine KinasesHumansImmunohistochemistryProspective StudiesBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesClinical trialGastric cancerHER2ImmunohistochemistryMulti-institutional study

Identifiers

PMID35765007
PMCPMC9238183
OpenAlexW4283647322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.